May 15, 2017 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock today, upsized from the original share offering of 2,500,000 shares of common stock, at a previously disclosed public offering price of $28.85 per share. The gross proceeds to Accelerate Diagnostics from the offering are approximately $79.3 million before deducting underwriting commissions and discounts, and estimated offering expenses payable by the company.
Accelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017
May 03, 2017 — Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending March 31, 2017 including signed customer evaluation contracts covering 169 instruments, 22 additional instruments converted into revenue generating placements, and revenue growth exceeding 325% of the same period in the prior year.
Accelerate Diagnostics Schedules Call to Review First Quarter 2017 Results for May 3rd
Apr 18, 2017 — Accelerate Diagnostics, Inc. announced today it will host a conference call on Wednesday, May 3rd, 2017 to discuss its first quarter 2017 financial results and commercial progress.
Fourth Quarter and Full Year 2016 Results
Feb 28, 2017 — Accelerate Diagnostics filed Fourth Quarter and Full Year 2016 financial results today. Access them directly on our website in the SEC filings section of our Investors page or through the Securities and Exchange Commission’s (SEC) website.
See all news
Enter your email address below for access to photos, logos and videos.
Connect with us
June 1–5, 2017
October 4–8, 2017
Stay up to date with Accelerate by joining our mailing list.Sign up today
May 10–13, 2017
Friday, May 5, 2017
April 22–25, 2017
March 26–28, 2017
March 21–27, 2017
11 au 13 Janvier 2017
Porte de Versailles a Paris
Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
Evaluation of Accelerate Pheno™ System in a Clinical Setting: Comparison of Identification and Antibiotic Susceptibility Test Results of 224 Prospective Positive Blood Cultures to Standard Laboratory Methods at Detroit Medical Center
Predicting the hVISA Phenotype Using a Novel in vitro Real-time Assessment of S. aureus Division Rates
Evaluation of the Accelerate Pheno™ system versus current blood culture ID/AST methods and potential impact on antimicrobial stewardship and patient management
Learn about ourTechnology